Keyphrases
Advanced Parkinson's Disease
16%
Amantadine
100%
Antagonistic Properties
16%
Anti-Parkinson
33%
Antiparkinsonian Agents
16%
Controlled Crosses
16%
Diary
33%
Dyskinesia
100%
Hyperfunctions
16%
Levodopa
100%
Levodopa Therapy
16%
Levodopa-induced Dyskinesia
16%
Motor Complications
16%
Motor Fluctuations
100%
Motor Response
16%
N-methyl-D-aspartate
16%
N-methyl-D-aspartate Receptor (NMDAR)
33%
N-methyl-D-aspartate Receptor Antagonist
16%
Parkinson Patients
16%
Parkinson's Disease
100%
Parkinsonian
16%
Placebo
33%
Placebo-controlled
16%
Primates
16%
Receptor Blockade
16%
Steady State
16%
Unified Parkinson's Disease Rating Scale (UPDRS)
33%
Pharmacology, Toxicology and Pharmaceutical Science
Amantadine
100%
Antiparkinson Agent
42%
Aspartic Acid
57%
Dyskinesia
100%
Levodopa
100%
Levodopa-Induced Dyskinesia
14%
Parkinson's Disease
100%
Placebo
42%
Primate Disease
14%
Receptor
28%